Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 15;15(10):12882-12894.
doi: 10.1021/acsami.3c01771. Epub 2023 Feb 28.

Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug

Olga O Krasnovskaya  1   2 , Roman A Akasov  3   4 , Daniil V Spector  1   2 , Kirill G Pavlov  1 , Anna A Bubley  1 , Vladimir A Kuzmin  5 , Alexey A Kostyukov  5 , Evgeny V Khaydukov  3   4 , Elena V Lopatukhina  1 , Alevtina S Semkina  6   7 , Kseniya Yu Vlasova  1   6 , Sergey A Sypalov  8 , Alexander S Erofeev  1   2 , Petr V Gorelkin  1   2 , Alexander N Vaneev  1   2 , Vita N Nikitina  1 , Dmitrii A Skvortsov  1 , Daria A Ipatova  1 , Dmitrii M Mazur  1 , Nikolay V Zyk  1 , Dmitry A Sakharov  9 , Alexander G Majouga  9 , Elena K Beloglazkina  1
Affiliations

Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug

Olga O Krasnovskaya et al. ACS Appl Mater Interfaces. .

Abstract

Controlled photoreduction of Pt(IV) prodrugs is a challenging task due to the possibility of targeted light-controlled activation of anticancer agents without affecting healthy tissues. Also, a conjugation of photosensitizers and clinically used platinum drugs into one Pt(IV) prodrug allows combining photodynamic therapy and chemotherapy approaches into one molecule. Herein, we designed the cisplatin-based Pt(IV) prodrug Riboplatin with tetraacetylriboflavin in the axial position. A novel Pt(IV) prodrug is able to act both as a photodynamic therapy (PDT) agent through the conversion of ground-state 3O2 to excited-state 1O2 and as an agent of photoactivated chemotherapy (PACT) through releasing of cisplatin under gentle blue light irradiation, without the requirement of a reducing agent. The light-induced behavior of Riboplatin was investigated using an electrochemical sensor in MCF-7 tumor spheroids. Photocontrolled cisplatin release and ROS generation were detected electrochemically in real time. This appears to be the first confirmation of simultaneous photoactivated release of anticancer drug cisplatin and ROS from a dual-action Pt(IV) prodrug observed from the inside of living tumor spheroids.

Keywords: PACT; PDT; Pt(IV) prodrugs; ROS; cisplatin; controlled release; nanoelectrode; riboflavin.

PubMed Disclaimer

LinkOut - more resources